Home › All Companies › CGON › Annual Report

CG Oncology, Inc. (CGON) — Annual Report

AI-Powered SEC Filing Analysis

← All CGON filings
Latest Annual Report Filed: 2026-02-27

Key Insights

  • CG Oncology, Inc. (CGON) is a biopharmaceutical company focused on the development of novel cancer therapies. The filing indicates the company has been actively raising capital through various financing activities, including a public offering, private placements, and an open market sale agreement.
  • CGON has established several key collaborations and licensing agreements, including with Kissei Pharmaceutical Co. Ltd. and Lepu Biotech Co. Ltd. These partnerships suggest the company is actively pursuing external research and development to advance its pipeline.
  • The company has been investing in its internal capabilities, including the development of manufacturing and laboratory equipment, as well as hiring additional personnel to support its commercial and development activities.
Sentiment: Positive Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-02-27. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for CG Oncology, Inc.

Current Report Quarterly Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.